logo
Climate change is disrupting the human gut in a new path to illness

Climate change is disrupting the human gut in a new path to illness

The Hindu08-05-2025

Climate-driven food shortage and undernourishment could affect the composition of the human gut microbiota, exacerbating the effects of climate change on human health, according to a new review article published in The Lancet Planetary Health.
The article comes on the heels of a growing number of studies that highlight the key role food and nutrition play in maintaining a healthy microbial population in the human gut, leading to better metabolic and intestinal health.
Diversity disrupted
According to the review, climate-induced changes in the yield and nutritional quality of plants, seafood, meat, and dairy could disrupt this microbial diversity, tipping the balance towards microbial strains associated with malnutrition and particular diseases.
The review also warns that these effects will be more pronounced in low and middle-income countries (LMICs) since these regions face the brunt of climate stressors, including higher temperature and atmospheric carbon dioxide, which affect their agricultural output and increase render deficiencies in these areas more common.
Indigenous communities that depend more than other demographic groups on local food sources and which have been shown to have greater gut microbial diversity may also be more susceptible to climate-related changes, the review reads.
Research has already found that high atmospheric carbon dioxide levels can diminish the quantity of plant micronutrients like phosphorus, potassium, zinc, and iron, along with protein concentrations in vital crops such as wheat, maize and rice. These effects add to the complexities that affect the gut microbiota.
While the effects of food and nutrition are direct, the review also examined the role of changes in water, soil, and other environmental microbiota as a result of climate change.
A fine balance
In another recent review, published in Dialogues in Health, researchers from the Indian Institute of Public Health, Gandhinagar, analysed the impact of heat on human and animal health in India. They found that reports of foodborne and waterborne infectious diseases and malnutrition increase with heat.
Although these findings mirror common knowledge about food and water-related illnesses in warmer weather, the resulting implications for gut dysbiosis — the imbalance in gut microbial populations — also need to be considered for future heat-related mitigation efforts, The Lancet review said.
'While we know and research various effects of climate change on human health, one aspect remains understudied — the effects of changing climate on the microbial communities in the human gut,' Elena Litchman, author of the review in The Lancet and the MSU Foundation professor of aquatic ecology at Michigan State University, said. 'This, in part, could be explained by the fact that researchers studying human microbiota do not necessarily think about it in a climate change context.'
The human gut is home to about 100 trillion bacteria, fungi, protozoa, and viruses. Bacteria are this group's predominant members. The microbes' overall diversity in the gut influences several aspects of human well-being, including immunity, maintaining glucose levels, and metabolism.
According to a 2018 analysis in The BMJ, lower bacterial diversity has been observed in atopic eczema, types I and II diabetes, and inflammatory bowel disease, among other conditions. Researchers are also exploring how gut dysbiosis changes the central nervous system and leads to neurological disorders.
More research attention
The gut microbiome — the collective genome of the microbes in the gut — has far more genes than the human genome, producing thousands of metabolites that affect the individual's health and development.
'Our understanding of the gut microbiota's role in human health is still evolving,' While climate change is a growing concern in this context, establishing cause and effect is difficult as there are many confounding factors,' Sachit Anand, a paediatric urologist and assistant professor at AIIMS, New Delhi, said. In his research, Anand examines the role of gut microbiota in congenital anomalies of the kidney and urinary tract.
He added that understanding the interactions between the microbiota, the host, and the environment is now gaining more research attention, especially when evaluating an individual's susceptibility to specific diseases. As climate change becomes a key influencing factor in this 'triad', its impact cannot be ignored moving forward, he said.
It may be tempting to examine these interdependencies in a linear manner: i.e. that climate-induced changes in crops affect the diet and thus the gut microbiota, or that climate-induced increases in temperatures make enteric infections more prevalent, ultimately disrupting the gut's microbial population. But both Litchman and Tarini Shankar Ghosh, assistant professor at Indraprastha Institute of Information Technology Delhi, warned that many of these stressors are often playing out simultaneously.
As a computational biologist, Ghosh is interested in patterns in data about the human gut microbiome.
'If you take the example of low-income groups residing in urban environments, you are looking at the impacts of temperature, pollution, lack of quality food, and water supply,' he explained. 'There are multiple factors that are disrupting the gut microbiota at the same time.'
A new science
Ghosh also said dysbiosis has been found to be a diagnostic signature in many disease states. According to him, this means it is not just the tipping of the balance towards unfavourable microbial populations that is concerning: dysbiosis also signals a loss of interdependence between 'normal' microbial strains, leading to a loss of several metabolic functions in the host.
'What we need right now is to generate more data to understand how the so-called good bacteria interact with each other and benefit the host. Data generation must go hand-in-hand with connecting this information to climate change, so we know what is happening,' Ghosh said.
Thus, Litchman said, a multidisciplinary approach with researchers from disparate fields coming together is vital to understand the effects of climate change on human gut microbiota. But along with a lack of awareness of climate change's effects, a paucity of funding programmes to enable such interdisciplinary and international research is a major impediment to future research of this nature, she added.
On the flip side, with advances in computational biology and metagenomics — analyses of the genetic makeup of microorganisms in a given environment — researchers are inching closer to unearthing some of the gut microbiota's secrets. For example, Indian Institute of Science Education and Research, Bhopal, professor Vineet Kumar Sharma has developed an open-access database named GutBugBD. It provides information about how the gut microbiome can interact with and alter specific nutraceuticals and drugs, paving the way for therapeutic approaches to modulate gut microbiota in response to various changes.
This is just the start, according to Sharma: 'At the moment, we are merely doing broader surveys of the gut microbiota to understand what is there and how they are functioning. Even if we introduce healthy microbiota through, say, probiotics, we cannot know if the response will be the same between two individuals. Each person's gut microbiota is unique, and understanding this uniqueness is important for the way forward.'
Sharmila Vaidyanathan is an independent writer from Bengaluru.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Maha's anti-venom pioneer targeted by predatory journal
Maha's anti-venom pioneer targeted by predatory journal

Time of India

time9 hours ago

  • Time of India

Maha's anti-venom pioneer targeted by predatory journal

Mumbai: The world of medical research is battling its own version of cyber frauds: predatory or 'pseudo' journals, deceptive publications that claim to be scholarly but rarely follow ethical publishing practices and seek hefty payment from authors. On Friday, Dr Himmatrao Bawaskar (75), a Mahad-based physician who won a Padma Shri in 2022 and is known for his rural Maharashtra medical practice and research, wrote in 'The Lancet' about his two-year struggle with a predatory journal that swiftly published his work, then started demanding 1,000 pounds and issued threats when he objected. "I received threatening emails stating they would take serious action and damage my reputation in India," he said. Mahad-based Dr Himmatrao Bawaskar, whose pioneering work in anti-venom for scorpions and snakes has been published in numerous peer-reviewed medical journals, was so "devastated" by his struggle with a predatory journal that he developed "anxiety, insomnia and palpitation". Within six months, the 75-year-old doctor lost 8 kgs and needed psychiatric help. In recent months, various medical associations across the world have voiced concern about the growing number of predatory journals. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Tausende schwärmen von diesem Nagelpilz-Gerät – wir haben es überprüft Med-Aktuell Undo The International Committee of Medical Journal Editors in Feb estimated there are over 15,000 such journals. While medical research paves the way for new treatments, these journals are undermining its credibility. Dr Bawaskar's ordeal began when he submitted his self-funded diabetes research to high-impact journals. After many rejections, a case report journal approached him. "In my submission to this journal, I stated I work without funding and would not be able to pay fees," he said. Yet the journal sent him a proof in a couple of days. "I was shocked—how could the peer review and publication process be completed so quickly? I again appealed, stating my inability to pay. The journal ignored my requests and proceeded to publish the article, then sent me an invoice with exorbitant fee," he added. The journal then sent threats and said they were giving him "a 40% discount." "But during a call with my son who is a cardiologist in the US, my wife mentioned my stress to him," said the doctor. His son identified the predatory nature of the journal and blocked their communications. While the doctor hasn't paid the journal, this experience has prompted him to work out a checklist. He said, "Since this episode, I have not attempted to publish again. Instead, I find fulfilment in seeing my patients recover and walk again—living testaments to my diagnosis and management; these are my true publications." Get the latest lifestyle updates on Times of India, along with Eid wishes , messages , and quotes !

This disease might be silently killing millions quietly, says research. Are you at risk?
This disease might be silently killing millions quietly, says research. Are you at risk?

Time of India

time14 hours ago

  • Time of India

This disease might be silently killing millions quietly, says research. Are you at risk?

A recent international study has revealed that millions of people in the US and Europe may be unknowingly living with a dangerous form of fatty liver disease. Published in The Lancet Regional Health Europe, the research indicates that a vast number of individuals are affected by metabolic dysfunction-associated steatotic liver disease (MASLD), with the majority still undiagnosed. Widespread but Largely Undetected The study examined populations in the United States, United Kingdom, Germany, and France, and found that approximately 20 million people across these countries have the more severe variant of MASLD known as metabolic dysfunction-associated steatohepatitis (MASH). Alarmingly, only about 2.5 million have received a formal diagnosis. This means roughly three-quarters of those with the disease—an estimated 16.7 million individuals—remain unaware of their condition. MASLD is the updated term for non-alcoholic fatty liver disease (NAFLD), and it affects people whose liver contains over 5% fat despite little or no alcohol intake. While many patients only develop the earliest and less severe stage known as simple fatty liver, the disease can progress without symptoms and cause serious damage over time. Progressive and Potentially Fatal MASH, the aggressive form of the disease, is associated with inflammation and can lead to fibrosis, or scarring of the liver. If not managed, it may progress to cirrhosis, a stage marked by irreversible liver damage and potential liver failure. The condition is also linked to higher risks of cardiovascular issues, chronic kidney disease, and liver cancer. The study's findings emphasize the urgency of early diagnosis, especially as MASH is particularly common among people with type 2 diabetes and those who are overweight or obese. Researchers noted that around two-thirds of individuals with type 2 diabetes are thought to have MASLD. Urgent Need for Diagnosis and Treatment Dr. Jeffrey Lazarus, the lead author of the study, stressed the economic and health burden posed by undiagnosed MASH. He pointed out that without a significant increase in diagnosis and treatment, the financial costs to healthcare systems could triple over the next two decades. Prof. Emmanouil Tsochatzis of University College London echoed this warning, stating that over 15 million people in the US and Europe are living with the most severe form of fatty liver disease without knowing it. He warned that both human suffering and economic consequences could worsen significantly if diagnosis rates do not improve. Traditionally, MASH has been diagnosed through liver biopsy, but newer, non-invasive tools such as blood tests, ultrasound, and MRI scans have made screening easier. Experts now recommend that individuals with type 2 diabetes, obesity combined with other risk factors, or persistently elevated liver enzymes undergo regular screening. Potential Role of Weight Loss Medications The study has also brought renewed attention to the potential of weight loss medications to help manage MASH. Dr. Paul Brennan, a hepatologist and co-author of the study, highlighted the promise of GLP-1 agonists like Wegovy and Mounjaro. These drugs work by reducing appetite and slowing digestion, leading to weight loss, which in turn may help reduce fat accumulation and scar tissue in the liver. Michael Betel, president of the Fatty Liver Alliance, stressed that individuals with type 2 diabetes or obesity are often not screened for MASH until significant liver damage has occurred. He called for broader liver health assessments and, when appropriate, the use of weight loss drugs as part of a comprehensive treatment strategy. A separate study released around the same time found that the diabetes drug dapagliflozin not only helps reduce blood sugar but also lowers fat and scarring in the liver, suggesting another potential treatment pathway. Risk Factors and Screening According to health authorities like the NHS, those at greater risk of MASLD include people who are overweight, have type 2 diabetes, high blood pressure, high cholesterol, metabolic syndrome, or are over the age of 50. Smoking and thyroid disorders may also increase the risk. Doctors typically begin diagnosis with blood tests that show elevated liver enzymes. If abnormalities are detected, further assessments such as imaging scans or liver elastography (FibroScan) are used to evaluate liver fat and fibrosis levels. With the growing prevalence of MASLD and MASH, the study underscores the critical importance of early screening, timely intervention, and broader public health awareness to address this hidden but escalating health threat.

Evidence of CAR T-cell therapy against cancers presented at US conference
Evidence of CAR T-cell therapy against cancers presented at US conference

Time of India

time5 days ago

  • Time of India

Evidence of CAR T-cell therapy against cancers presented at US conference

New Delhi: Studies have provided evidence of the effectiveness of CAR T-cell therapy against gastric and brain tumours. The papers, presented at the annual meeting of the American Society of Clinical Oncology [ASCO] 2025, held from May 30 to June 3 in Chicago, US, have also been published in journals, including The Lancet and Nature Medicine. Treating cancer using CAR T-cell therapy involves modifying genes in one's T-cells - a type of immune cell - to help fight cancer. In The Lancet paper, that revealed results of phase 2 clinical trials , 156 patients with advanced gastric or gastro-oesophageal junction cancer - and who were resistant to "at least two previous lines of treatment" - were randomly assigned to receive 'satri-cel' or an intervention of physician's choice. Satri-cel, or 'Satricabtagene autoleucel' - a CAR T-cell therapy -- showed "encouraging activity" in phase 1 clinical trials in treating patients with advanced gastric or gastro-oesophageal junction cancer, the team, including researchers from China's Peking University Cancer Hospital and Institute, said. A phase-1 trial primarily looks at establishing a new drug's safety and dose characteristics in about 20-100 healthy volunteers, while a 'phase-2' trial provides evidence of the effectiveness of the experimental drug in about 100-300 volunteers or participants. "In this multicentre, randomised, phase 2 study, satri-cel was associated with a statistically significant increase in progression-free survival and clinically meaningful increase in overall survival compared with TPC (treatment of physician's choice), along with a manageable safety profile in patients," the authors wrote. They added that it is the "first randomised controlled study of a CAR T-cell therapy in solid tumours". In the second study, published in the Nature Medicine journal, researchers from the University of Pennsylvania, US, said that CAR T-cell therapy "shows promise for slowing tumour growth in a notoriously aggressive and fast-growing brain cancer ". The phase-1 trial involved 18 patients with glioblastoma who received the treatment. "Tumour regression (becoming smaller) occurred in eight of 13 patients (62 per cent) with measurable disease," the authors wrote. In March, a CAR T-cell therapy, indigenously developed by researchers from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, showed a 73 per cent response rate in patients of leukaemia and lymphoma, who either relapsed following a period of remission or were resistant to treatment. The results of the phase 1 and 2 clinical trials are published in The Lancet Haematology journal. PTI

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store